Robert W. Baird Cuts Henry Schein (NASDAQ:HSIC) Price Target to $82.00

Henry Schein (NASDAQ:HSIC) had its price target lowered by Robert W. Baird from $92.00 to $82.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research analysts also recently commented on the stock. Barrington Research lowered their price target on shares of Henry Schein from $92.00 to $82.00 and set an outperform rating for the company in a report on Wednesday. Piper Sandler reiterated an overweight rating and issued a $86.00 target price on shares of Henry Schein in a report on Friday, June 21st. Baird R W upgraded Henry Schein from a hold rating to a strong-buy rating in a research report on Monday, July 22nd. Evercore ISI dropped their price objective on shares of Henry Schein from $72.00 to $70.00 and set an in-line rating for the company in a research note on Wednesday. Finally, UBS Group lowered their target price on shares of Henry Schein from $82.00 to $80.00 and set a neutral rating for the company in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and an average target price of $77.90.

Henry Schein Price Performance

Shares of HSIC traded up $0.78 during mid-day trading on Wednesday, hitting $68.94. 2,399,686 shares of the stock were exchanged, compared to its average volume of 1,227,769. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The company has a market cap of $8.83 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87. Henry Schein has a 52-week low of $60.01 and a 52-week high of $82.63. The firm has a 50-day moving average of $67.73 and a two-hundred day moving average of $71.55.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The company had revenue of $3.10 billion for the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter in the previous year, the business posted $1.31 earnings per share. Henry Schein’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts predict that Henry Schein will post 5.16 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

Several large investors have recently added to or reduced their stakes in HSIC. Edgestream Partners L.P. purchased a new position in shares of Henry Schein during the second quarter worth approximately $1,418,000. Dimensional Fund Advisors LP raised its position in Henry Schein by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,634,384 shares of the company’s stock valued at $104,764,000 after purchasing an additional 149,517 shares in the last quarter. Keene & Associates Inc. lifted its holdings in shares of Henry Schein by 14.3% in the 2nd quarter. Keene & Associates Inc. now owns 5,150 shares of the company’s stock worth $330,000 after buying an additional 645 shares during the period. Thompson Siegel & Walmsley LLC bought a new position in shares of Henry Schein during the 2nd quarter worth $46,683,000. Finally, Oppenheimer Asset Management Inc. increased its stake in shares of Henry Schein by 12.5% during the second quarter. Oppenheimer Asset Management Inc. now owns 5,459 shares of the company’s stock valued at $350,000 after buying an additional 606 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.